Mechanism of action and pharmacological effect
The enzyme dihydrofolate reductase plays a key role in microbial metabolism by reducing dihydrofolate (DHF) to tetrahydrofolate (THF). This process is critical for the subsequent synthesis of purines and pyrimidines—the main building blocks of DNA—as well as for the methylation of dUMP to dTMP.
Drugs of this group, such as trimethoprim and pyrimethamine, act as folic acid analogues and perform competitive inhibition of DHFR. The selectivity of the drugs is based on genetic and structural differences between human and pathogen enzyme isoforms.
Characteristics of individual agents
- Trimethoprim has a pronounced bacteriostatic effect. As monotherapy, it is used for uncomplicated urinary tract infections (UTIs) since it is excreted unchanged by the kidneys. However, it is more commonly used in combination with sulfonamides.
- Pyrimethamine selectively inhibits protozoan DHFR. In clinical practice, it is used in combination with sulfadiazine for the treatment of toxoplasmosis (currently being the only effective chemotherapeutic agent) and was previously used for malaria.
Synergy with sulfonamides and co-trimoxazole
Combining DHFR inhibitors with sulfonamides (e.g., as part of co-trimoxazole) transforms two bacteriostatic agents into a potent combination with a bactericidal effect.
The essence of synergy lies in the sequential blockade of metabolic pathways:
- Sulfamethoxazole reduces the intracellular concentration of dihydrofolic acid.
- The drop in substrate concentration enhances the efficacy of trimethoprim by reducing competition for enzyme binding.
This combination helps overcome microbial resistance. Even if a bacterium produces an altered DHFR with low drug affinity, this mutant enzyme also has reduced affinity for the natural substrate. The sulfonamide depletes dihydrofolic acid reserves to a critical level, making the mutated enzyme non-functional.
Pharmacokinetics and safety of co-trimoxazole
The success of the combination drug sulfamethoxazole + trimethoprim is due to the equal elimination rate of both components (duration of action is 12 hours).
- Absorption and distribution: The drug is well absorbed in the gastrointestinal tract and penetrates various tissues and fluids, achieving high concentrations in bronchial secretions, bile, urine, the prostate, and brain tissue (crosses the blood-brain barrier).
- Indications: Used for infections of the respiratory tract (including Pneumocystis pneumonia), ENT organs, urogenital system, as well as brucellosis, malaria, and toxoplasmosis.
- Limitations: Contraindicated in pregnancy, severe hepatic and renal impairment, and blood disorders.
Briefly: answers to topical questions
What is the full spectrum of antimicrobial action of co-trimoxazole?
Co-trimoxazole has a broad spectrum of bactericidal action, including microflora resistant to conventional sulfonamides and other antibiotics. The activity spectrum of the drug includes:
- Gram-negative flora — causative agents of urinary tract infections.
- Haemophilus ducreyi — causative agent of chancroid.
- Toxoplasma gondii — causative agent of toxoplasmosis (as part of combination therapy).
- Causative agents of specific infections — brucellosis, malaria, Pneumocystis pneumonia.
The drug is also active against pathogens of respiratory tract infections, ENT infections, and surgical and wound infections.
What side effects and complications are characteristic of co-trimoxazole therapy?
The side effects of co-trimoxazole are similar to those of resorptive sulfonamides. The drug is contraindicated in severe hepatic and renal dysfunction, hematopoiesis disorders, and pregnancy.
What are the mechanisms of microbial resistance to co-trimoxazole?
The main mechanism of resistance to co-trimoxazole is target modification. Resistance develops through the expression of a structurally altered dihydrofolate reductase (DHFR) that acquires low affinity for the drug.
Resistance to the combination drug develops much slower than to single agents. Since sulfamethoxazole and trimethoprim block different enzymes, microbial survival requires simultaneous mutation in two different loci, which is an unlikely event.
Trimethoprim plus sulfonamide hit microbes at two steps, turning a static drug into a cidal one!
Class and exam questions
What is the biochemical effect of DHFR inhibitors?
The drugs block the reduction of dihydrofolate to tetrahydrofolate, which disrupts purine nucleotide synthesis and the methylation of dUMP to dTMP, halting DNA synthesis in microorganisms.
Why does the combination of trimethoprim and sulfonamide produce a bactericidal effect?
Sulfonamide reduces the concentration of the substrate (dihydrofolate) in the cell, which increases the efficacy of trimethoprim by reducing competition for the enzyme. Simultaneous blockade of two metabolic steps leads to bacterial cell death.
What are the main pharmacokinetic features of co-trimoxazole?
The components are selected with identical elimination rates (approximately 12 hours). The drug is well absorbed in the GI tract, crosses the blood-brain barrier, and achieves high concentrations in urine, bile, bronchial secretions, and the prostate gland.
What else to study on this topic
- Structural differences between human and pathogen dihydrofolate reductase isoforms
- Mechanisms of bacterial drug resistance to DHFR inhibitors
- Specifics of co-trimoxazole use in Pneumocystis pneumonia
- Comparative profile of co-trimoxazole analogues (Lidaprim, Sulfaton, Poteseptil)
- Toxicological profile and side effects of resorptive sulfonamides
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Dihydrofolate reductase inhibitors" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Antibacterial Chemotherapeutic Agents"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.